NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
TEVA
Teva Pharmaceutical Industries Limited
TEVA has a slight edge over NVO overall on the model score.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TEVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
TEVA's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over TEVA in the historical PE scenario, which offers more potential upside but is not a forecast.
TEVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.18 | -86% |
| Forward | 15x | $43.65 | — |
| Fair | 26x | $11.34 | -74% |
| Expensive | 59x | $25.80 | -41% |
| Current | 99x | $43.65 | — |
Historical ranges are pointers, not guarantees.
TEVA's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TEVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TEVA's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TEVA on earnings, with more consistent year-over-year improvement.
TEVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +542% |
| Q3 2026 | $0.44 | -27% |
| Q2 2026 | $0.61 | +$0.77 |
| Q1 2026 | $1.34 | +$2.49 |
| Q4 2025 | $1.21 | +$2.66 |
| Q3 2025 | $0.60 | +$1.44 |
| Q2 2025 | -$0.16 | +$0.22 |
| Q1 2025 | -$1.15 | -$0.75 |
| Q4 2024 | -$1.45 | -$0.99 |
TEVA earned $0.44 per share over the past year, down 27% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TEVA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TEVA on profitability, with a higher operating margin.
TEVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | -1.9% |
| Q2 2026 | $4.1B | -0.8% |
| Q1 2026 | $4B | +2.3% |
| Q4 2025 | $1.5B | -65% |
| Q3 2025 | $4.5B | +3.4% |
| Q2 2025 | $4.2B | +0.3% |
| Q1 2025 | $3.9B | +1.9% |
| Q4 2024 | $4.2B | -5.1% |
TEVA's revenue is shrinking: $4.4B last quarter, down 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -3.4 points |
| Q2 2026 | -5.6% | -17 points |
| Q1 2026 | 16% | +3 points |
| Q4 2025 | 20% | +21 points |
| Q3 2025 | 20% | +21 points |
| Q2 2025 | 11% | +11 points |
| Q1 2025 | 13% | +19 points |
| Q4 2024 | -0.7% | -17 points |
TEVA's operating margin was 16% last quarter, down 3.4 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
TEVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121M | -48% |
| Q2 2026 | $307M | +134% |
| Q1 2026 | -$208M | +$24M |
| Q4 2025 | $1B | +128% |
| Q3 2025 | $233M | -57% |
| Q2 2025 | $131M | +2083% |
| Q1 2025 | -$232M | +$16M |
| Q4 2024 | $446M | -58% |
TEVA generated $1.2B in free cash flow over the past year, up 114% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TEVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TEVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +18M shares |
| 1 year | +1.6% | +19M shares |
| 3 years | +4.2% | +48M shares |
| 5 years | +6.7% | +74M shares |
| Available history | +8.4% | +92M shares |
TEVA has 1.2B diluted shares, up 1.6% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over TEVA on leverage, with a lower net debt burden relative to earnings.
TEVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.9x | High |
| Q2 2026 | 6.8x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 5.2x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 10.5x | High |
| Q4 2024 | 21.6x | High |
TEVA's net debt is about 6.9 years of its operating earnings (EBITDA), up from 5.2 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TEVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.1 | Overbought |
| Stochastic | 93.7 | Overbought |
TEVA's weekly RSI is 70 (overbought) and its Stochastic is 94 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over TEVA on valuation relative to its sector.
TEVA PE vs Healthcare Sector
| Metric | TEVA | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 26x | 284% above |
| PE % | 100 | 29 | 71 pts above |
TEVA is trading at 99x earnings, a 284% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TEVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.1 | 6.1% above |
| 20 week MA | $37.6 | 16% above |
| 50 week MA | $34.4 | 27% above |
| 100 week MA | $26.3 | 66% above |
| 200 week MA | $19.4 | 125% above |
TEVA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TEVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.96 | $9.83 | -1.3% |
| 2021 | $9.83 | $8.46 | -14% |
| 2022 | $8.46 | $9.24 | +9.2% |
| 2023 | $9.24 | $10.4 | +13% |
| 2024 | $10.4 | $22.8 | +118% |
| 2025 | $22.8 | $31.9 | +40% |
| 2026 YTD | $31.9 | $43.7 | +37% |
TEVA has the edge over NVO on returns for 2026, with the stronger performance.